The pharmacy landscape has evolved considerably over the past year, shining a spotlight on pharmacy “patient steering”, the practice of directing patients to certain preferred pharmacies. Though Quebec has long required that...more
Canada is an attractive market for pharmaceutical manufacturers. While universal healthcare does not currently extend to drugs in an outpatient setting, most Canadian consumers have some form of drug coverage through...more
1. PAAB’s Accelerated Review Options -
In July 2022, the Pharmaceutical Advertising Advisory Board (PAAB) will launch four Accelerated Review Options (ARO) to its standard pre-clearance pathway, covering a range of...more
Since 2018, Health Canada has undertaken an initiative to adapt its regulatory approach to better support digital health technologies, specifically medical devices. Key focus areas include artificial intelligence, software as...more
12/1/2021
/ Artificial Intelligence ,
Cybersecurity ,
Digital Health ,
Health Care Providers ,
Health Information Technologies ,
Innovative Technology ,
Life Sciences ,
Machine Learning ,
Medicines and Healthcare Products Regulatory Agency (MHRA) ,
Popular ,
Telehealth ,
Telemedicine
The Canadian Agency for Drugs and Technologies in Health (CADTH) published an interesting new report on January 29, 2021 about Health Technology Trends to Watch. The report identifies the following list of emerging trends...more
3/30/2021
/ 3D Printing ,
Artificial Intelligence ,
Augmented Reality ,
CADTH ,
Canada ,
Connected Items ,
Coronavirus/COVID-19 ,
Diagnostic Tests ,
Health Canada ,
Health Technology ,
Life Sciences ,
Medical Devices ,
Pain Management ,
Pharmaceutical Industry ,
Popular ,
Regenerative Medicine ,
Telehealth ,
Virtual Reality ,
Virus Testing
UPDATE: The Regulations Amending Certain Regulations Concerning Drugs and Medical Devices (Shortages) were published in the Canada Gazette on September 1, 2021. These amendments are intended to provide Health Canada with...more
12/18/2020
/ Advertising ,
Canada ,
Clinical Trials ,
Coronavirus/COVID-19 ,
Food & Drug Regulations ,
Health Canada ,
Imports ,
Infectious Diseases ,
Interim Measures ,
Life Sciences ,
Medical Devices ,
New Guidance ,
Pharmaceutical Industry ,
Prescription Drugs ,
Proposed Amendments ,
Record Retention ,
Supply Chain ,
Supply Shortages ,
Vaccinations
On September 28, 2020, the Regulations Amending Certain Regulations Made under the Food and Drugs Act (Sale of a New Drug for Emergency Treatment) (Regulations) came into force. Health Canada subsequently published a Notice,...more
11/9/2020
/ Canada ,
Controlled Substances ,
Final Guidance ,
Food and Drug Act ,
Health Canada ,
Health Care Providers ,
Hospitals ,
Life Sciences ,
Manufacturers ,
New Regulations ,
Patented Medicine Prices Review Board (PMPRB) ,
Pharmaceutical Industry ,
Pharmacies ,
Physicians ,
Prescription Drugs
In This Issue:
Ontario Court of Appeal allows Sanofi and Schering to plead that Federal Court ramipril patent invalidity decision was flawed due to “promise doctrine” -
In an action by Apotex for compensation from...more
12/6/2018
/ Apotex ,
Appeals ,
Biosimilars ,
CADTH ,
Canada ,
Eli Lilly ,
Lack of Novelty ,
Leave to Appeal ,
Life Sciences ,
Motion To Strike ,
Patent Invalidity ,
Patented Medicine Prices Review Board (PMPRB) ,
Patents ,
Pharmaceutical Patents ,
PMNOC Regulations ,
Promise Doctrine ,
Proposed Amendments ,
Remedies ,
Sandoz ,
Supreme Court of Canada ,
Teva Pharmaceuticals